Eligible physicians were hepatologists (France, Italy and the UK), gastroenterologists (Germany, Italy, Spain and the UK), gastroenterologists with a subspecialization in hepatology (Germany and Spain), hepato-gastroenterologists (France only), endocrinologists (all countries) and diabetologists (all countries). Physicians were managing ten or more patients with NASH per month and personally responsible for NASH management decisions. Patients had to be aged 18 years or older, with a physician-confirmed diagnosis of NASH obtained via liver biopsy and/or non-invasive test. In this analysis, patients had to have both a PSFS plus a VCTE test and/or data enabling retrospective calculation of a FIB-4 score. Patients could not be participating in NASH clinical trials at the time of data collection.
The survey was performed in accordance with relevant guidelines and in line with the principles of the Declaration of Helsinki; ethics approval was obtained from Freiburg Ethics Commission International (Approval No. 017/1931). All patients provided written informed consent for use of their data, which were anonymized and aggregated. No medication was provided and no tests or investigations were performed as part of this research. No hypothesis was developed or tested.
The survey was performed in accordance with relevant guidelines and in line with the principles of the Declaration of Helsinki; ethics approval was obtained from Freiburg Ethics Commission International (Approval No. 017/1931). All patients provided written informed consent for use of their data, which were anonymized and aggregated. No medication was provided and no tests or investigations were performed as part of this research. No hypothesis was developed or tested.
